The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | BMS-986393, a novel anti-GPRC5D CAR-T cell therapy, in multiple myeloma
Targeting GPRC5D has resulted in novel therapies for multiple myeloma. Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of results from a Phase I study (NCT04674813) of BMS-986393 (CC-95266), a GPRC5D-targeted CAR-T cell therapy for relapsed/refractory (R/R) multiple myeloma. 67 heavily pre-treated patients were enrolled and demonstrated promising efficacy. The incidence of adverse events (AEs) such as cytokine release syndrome (CRS) was similar to other CAR-T cell therapies. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory boards: Janssen, BMS, Takeda, Sanofi, GPCR Therapeutics, GSK
